Mozart is developing CD8 Treg modulators for the treatment of autoimmune and inflammatory diseases.
Regulatory CD8 T cells play a key role in regulating self-tolerance by selectively probing for and eliminating auto-reactive and pathogenic CD4 T cells and possibly other immune cells. However, in autoimmune disease, this network fails to control the activation and expansion of pathogenic CD4 T cells, resulting in a downstream cascade of inflammatory events that ultimately can lead to tissue destruction.
We are targeting the regulatory CD8 T cell network to counteract early events in the inflammatory cascade. Therapeutic modulation of this network is designed to restore the functions of CD8 Tregs to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and inflammatory diseases.
CD8 Treg modulators are disease modifying therapeutic molecules that selectively target the regulatory CD8 T cell network to counteract early events in the autoimmune inflammatory cascade. CD8 Treg Modulators are designed to restore the intrinsic functions of regulatory CD8 T cells to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and other inflammatory diseases.
A Newly Discovered Regulatory CD8 T Cell Network Has The Potential To Regulate And Eliminate Pathogenic CD4 T Cells In Autoimmune Mediated Disease Of The Gut | 2022 Digestive Disease Week® (DDW) Conference, May 2022, Presentation # sa1117
Bispecific CD8 Treg modulators regulate a novel regulatory CD8 T cell network and eliminate pathogenic CD4 T cells in live cell co-culture system | American Association of Immunologists (AAI) Annual Meeting, May 2022, Abstract # 1090
Demonstration of regulatory CD8 T cell prevalence, phenotype, and functions in autoimmune patients treated with a tolerizing peptide vaccine | American Association of Immunologists (AAI) Annual Meeting, May 2022, Abstract # 889